Literature DB >> 17465258

Brain radiotherapy during treatment with anticonvulsant therapy as a trigger for toxic epidermal necrolysis.

Giulio Metro1, Simona Pino, Domenica Pellegrini, Giorgio Sacerdoti, Alessandra Fabi.   

Abstract

Toxic epidermal necrolysis (TEN) is a severe mucocutaneous syndrome that can be occasionally caused by anticonvulsant drugs. In some cases, cranial irradiation may act as a precipitating factor. Thus, in cancer patients who suffer from brain metastases and are administered antiepileptic drugs for seizure prophylaxis, the risk of developing TEN after receiving palliative brain radiotherapy cannot be ignored. We is reported. The case of a young patient with non-small cell lung cancer (NSCLC) treated with prophylactic phenobarbital who developed TEN within a few days of completing cranial radiotherapy for brain metastases is reported. To minimize the risk of TEN in patients undergoing brain radiotherapy, prophylactic anticonvulsant therapy is recommended only after an accurate measurement of the true benefits. Alternatively, discontinuation of antiepileptic treatment before the initiation of brain radiotherapy, or the use of anticonvulsants associated with a lower risk of developing cutaneous reactions might be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465258

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

Review 1.  Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches.

Authors:  Jeffrey M Politsky
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

2.  Phenytoin- and cranial radiotherapy-induced toxic epidermal necrolysis treated with combination therapy: systemic steroid and intravenous immunoglobulin.

Authors:  E Fidan; M Fidan; F Ozdemir; H Kavgaci; F Aydin
Journal:  Med Oncol       Date:  2011-02-24       Impact factor: 3.064

Review 3.  Seizures and epilepsy in cancer: etiologies, evaluation, and management.

Authors:  Jai Grewal; Harpreet K Grewal; Arthur D Forman
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.